Personal details

Name
Adjunct Associate Professor David Leavesley
Position(s)
Adjunct Associate Professor
Faculty of Health,
School - Biomedical Sciences,
Research - Biomedical Sciences
IHBI Membership
Institute of Health Biomedical Innovation (IHBI),
IHBI Health Projects,
IHBI Biomedical Sciences - IPTM
Discipline *
Biochemistry and Cell Biology, Medical Biotechnology, Medical Biochemistry and Metabolomics
Phone
+61 7 3138 6188
Fax
+61 7 3138 6030
Email
Location
View location details (QUT staff and student access only)
Qualifications

Doctor of Philosophy (University of London)

* Field of Research code, Australian and New Zealand Standard Research Classification (ANZSRC), 2008

Biography

Research theme: Health
Research discipline: Cell and Molecular Biosciences
Research program: Tissue Repair & Regeneration
Research area

  • Vitronectin-growth factor complexes in tissue repair

Associate Professor Leavesley and his team have discovered that cellular and tissue biological responses are enhanced when growth factors are complexed with the extracellular matrix protein, vitronectin. He has discovered that the enhanced response is triggered by the co-activation of cell surface receptors. In this project, he is producing novel recombinant chimeric proteins to mimic the effects the vitronectin-growth factor complex. These proteins will be useful for therapeutic, regenerative medicine and industrial cell culture applications and will be more cost effective than the current multimeric protein complexes.

  • Multiprotein complexes for ex vivo tissue cultivation

Tissue grown ex vivo for clinical applications currently require animal-derived cells and/or non-defined products for their survival and propagation in the laboratory; these reagents can potentially infect patients who receive these ex vivo grown tissues. This project seeks to identify the essential components provided by these reagents in order to ultimately facilitate the development of a fully synthetic and defined culture system. This improvement will provide safer, cost-effective grafts and cell-based therapies that will benefit patients.

  • Wound repair in diabetes and vascular disease

Non-healing (chronic) ulcers in the elderly and infirm represent an important community-wide challenge frequently result from vascular disease and diabetes. Patient quality of life is diminished and burdens the healthcare sector at least $1 billion per year. This research project is testing a new topical multiprotein therapy designed to have improved activity in wounds. The project is a collaboration between scientists and doctors in Australia (QUT, University of Western Australia) and Canada. Many wound types may ultimately benefit from this treatment.

This information has been contributed by Adjunct Associate Professor David Leavesley.

Publications


For more publications by this staff member, visit QUT ePrints, the University's research repository.

Awards

Awards and recognition

Type
Academic Honours, Prestigious Awards or Prizes
Reference year
2010
Details
Vice Chancellor's Award for Excellence - Wound Management CRC Bid Team. 'In recognition of exceptional sustained performance and outstanding achievement in leadership.'
Type
Appointment to State/National/International Reference Group or Government Committees
Reference year
2012
Details
International Expert Adviser to Australia-China Tissue Engineering Centre, Ningxia Medical University, Yinchuan, China.
Type
Committee Role/Editor or Chair of an Academic Conference
Reference year
2011
Details
Invited Co-Chair, 4th Indo-Australian Conference on Biomaterials, Tissue Engineering and Drug Delivery Systems; 25th Anniversary Meeting of Society for Biomaterials & Artificial Organs - India (SBAO); 4th Annual Meeting of Society for Tissue Engineering & Regenerative Medicine (India) (STERMI), February 10-12, 2011, Gujarat, India
Type
Committee Role/Editor or Chair of an Academic Conference
Reference year
2012
Details
Convener and Chair of 5th Australian-Indian Biotechnology, Implants Tissue Engineering and Drug Delivery Systems Conference, Barrosa Valley, April 2013.
Type
Other
Reference year
2004
Details
Formation and successful IPO of a company, Tissue Therapies, on the Australian Stock Exchange. The company was formed specifically to commercialise the growth factor:vitronectin technology (VitroGro) which I co-discovered, patented and co-developed. The company listed on the ASX on March 19 2004 and unusually for a small biotech company, shares continue to trade well as the company is meeting its key commercialisation milestones. The technology for the serum-free cultivation of mammalian cells, including those used for the production of clinical skin grafts and the expansion of human embryonic stem cells, was licensed to Invitrogen Corporation in January 2007. Clinical trial of the technology for use as topical biologic to promote healing of diabetic and venous ulcers on the other hand is currently on-going in Toronto, Canada, and in Fremantle, Western Australia.

Research projects

Grants and projects (Category 1: Australian Competitive Grants only)

Title
Modelling Cell Invasion Incorporating the Epithelial to Mesenchymal Transition: Exploring Therapies to Control Wound Healing and Cancer Progression
Primary fund type
CAT 1 - Australian Competitive Grant
Project ID
DP120100551
Start year
2012
Keywords
Mathematical Biology; Mathematical Modelling; Multiscale Modelling; Cell Invasion
Title
Improved ex-vivo culture of keratinocytes for clinical applications
Primary fund type
CAT 1 - Australian Competitive Grant
Project ID
553028
Start year
2009
Keywords
Clinical cell culture; Feeder-cell free; Burns; Wounds; Clinical Grafts
Title
Development and Pre-clinical Evaluation of a Novel Wound Dressing Treatment for Chronic Ulcers
Primary fund type
CAT 1 - Australian Competitive Grant
Project ID
497266
Start year
2008
Keywords
Skin; Wound Healing; Venous Leg Ulcers; Tissue Regeneration; Matrix Metalloproteinase; Bisphosphonate
Title
Molecularly Engineered Cell-instructive Hydrogels for Enhanced Tissue Regeneration
Primary fund type
CAT 1 - Australian Competitive Grant
Project ID
DP0877992
Start year
2008
Keywords
Wound Healing; Insulin Like Growth Factor; Vitronectin; Extracellular Matrix; Biomaterial; Hydrogel;

Supervision